STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
A Roivant lung disease drug has succeeded in a mid-stage study. But the drug’s origins are another fascinating aspect to the story.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.